By rooting through files stored on Google Cloud, a researcher says he recovered 13 early coronavirus sequences that had disappeared from a database last year.
Author: CARL ZIMMER
CureVac’s Covid-19 Vaccine Disappoints in Clinical Trial
A preliminary analysis showed that CureVac’s mRNA vaccine had an efficacy of just 47 percent. “This is pretty devastating for them,” one expert said.
We’ll Probably Need Booster Shots for Covid-19. But When? And Which Ones?
Scientists are asking a lot of questions about Covid-19 booster shots, but they don’t yet have many answers. Here’s what they know so far.
This New Covid Vaccine Could Bring Hope to the Unvaccinated World
The German company CureVac hopes its RNA vaccine will rival those made by Moderna and Pfizer-BioNTech. It could be ready next month.
A new study hints at a reason the J.&J. and AstraZeneca vaccines may cause blood clots in rare cases.
A panel of experts advising the Centers for Disease Control and Prevention is discussing rare blood clots that health officials have investigated in Johnson & Johnson coronavirus vaccine recipients.
To Speed Vaccination, Some Call for Delaying Second Shots
Stretching the time between the first and second doses would greatly accelerate the rate at which people get at least partial protection. But some experts fear it could also lead to new variants.
Researchers Are Hatching a Low-Cost Covid-19 Vaccine
A new formulation entering clinical trials in Brazil, Mexico, Thailand and Vietnam could change how the world fights the pandemic.
Researchers Are Hatching a Low-Cost Coronavirus Vaccine
A new formulation entering clinical trials in Brazil, Mexico, Thailand and Vietnam could change how the world fights the pandemic.
Virus Variant in Brazil Infected Many Who Had Already Recovered From Covid-19
The first detailed studies of the so-called P.1 variant show how it devastated a Brazilian city. Now scientists want to know what it will do elsewhere.
Virus Variant in Brazil Infected Many Who Had Already Recovered From Covid-19
The first detailed studies of the so-called P.1 variant show how it devastated a Brazilian city. Now scientists want to know what it will do elsewhere.